Skip to main content

Drug Interactions between bupivacaine / dexamethasone / epinephrine and rifabutin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

dexAMETHasone rifabutin

Applies to: bupivacaine / dexamethasone / epinephrine and rifabutin

MONITOR: Rifampin may induce the hepatic metabolism of corticosteroids, possibly reducing their therapeutic effect. The elimination half-life of corticosteroids has been shown to be reduced by up to 45% when rifampin is coadministered. Theoretically, rifabutin could interact with corticosteroids in a similar manner.

MANAGEMENT: Patients should be monitored for altered corticosteroid effects. Dosage increases may be necessary. Two- to threefold increases in prednisolone dosage have been recommended.

References (7)
  1. Venkatesan K (1992) "Pharmacokinetic drug interactions with rifampicin." Clin Pharmacokinet, 22, p. 47-65
  2. Bergrem H, Refvem OK (1983) "Altered prednisolone pharmacokinetics in patients treated with rifampicin." Acta Med Scand, 213, p. 339-43
  3. Powell-Jackson PR, Gray BJ, Heaton RW, et al. (1983) "Adverse effect of rifampicin administration on steroid-dependent asthma." Am Rev Respir Dis, 128, p. 307-10
  4. Kyriazopoulou V, Parparousi O, Vagenakis AG (1984) "Rifampicin-induced adrenal crisis in Addisonian patients receiving corticosteroid replacement therapy." J Clin Endocrinol Metab, 59, p. 1204-6
  5. McAllister WA, Thompson PJ, Al-Habet SM, Rogers HJ (1983) "Rifampicin reduces effectiveness and bioavailability of prednisolone." Br Med J, 286, p. 923-5
  6. Lee KH, Shin JG, Chong WS, Kim S, Lee JS, Jang IJ, Shin SG (1993) "Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin." Eur J Clin Pharmacol, 45, p. 287-9
  7. Strayhorn VA, Baciewicz AM, Self TH (1997) "Update on rifampin drug interactions, III." Arch Intern Med, 157, p. 2453-8

Drug and food interactions

Moderate

EPINEPHrine food

Applies to: bupivacaine / dexamethasone / epinephrine

MONITOR: Coadministration of two or more sympathomimetic agents may increase the risk of adverse effects such as nervousness, irritability, and increased heart rate. Central nervous system (CNS) stimulants, particularly amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.

MANAGEMENT: Caution is advised if two or more sympathomimetic agents are coadministered. Pulse and blood pressure should be closely monitored.

References (7)
  1. Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr (1979) "Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients." Psychiatry Res, 1, p. 45-52
  2. Cavanaugh JH, Griffith JD, Oates JA (1970) "Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man." Clin Pharmacol Ther, 11, p. 656
  3. (2001) "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc
  4. (2001) "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals
  5. (2001) "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals
  6. (2001) "Product Information. Focalin (dexmethylphenidate)." Mikart Inc
  7. (2002) "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer